How tirzepatide works: the dual-agonist science, explained
Two incretin receptors, one molecule. The mechanism behind tirzepatide's results — appetite, gastric emptying, glucose control — and why it doses once a week.
The incretin system, briefly
After you eat, your gut releases hormones called incretins that tell the pancreas to release insulin — the "incretin effect." Two matter here: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). GLP-1 slows stomach emptying, signals fullness to the brain, and boosts glucose-dependent insulin secretion. GIP also enhances insulin response and appears to influence fat metabolism and appetite regulation through its own receptors. Naturally, both hormones are broken down within minutes; the drugs are engineered to resist that breakdown and act for days.
Why activating two receptors beats one
Semaglutide is a GLP-1 receptor agonist — it mimics one incretin. Tirzepatide is a single molecule that activates both the GLP-1 and GIP receptors. The hypothesis, borne out in the SURMOUNT-5 head-to-head where tirzepatide reached 20.2% versus semaglutide's 13.7%, is that engaging both incretin pathways produces additive or complementary metabolic effects — greater appetite suppression and glucose control than GLP-1 alone. The mechanism isn't fully settled science, but the outcome gap is consistent across independent trials.
From receptors to real-world results
The receptor activity translates into four practical effects patients notice: appetite falls, meals feel satisfying sooner (delayed gastric emptying), blood-sugar swings flatten, and — over months — body weight and cardiometabolic markers improve. In SURMOUNT-5, tirzepatide also outperformed on secondary cardiometabolic endpoints including blood pressure and lipids. The same delayed gastric emptying that drives fullness is also why nausea appears during escalation — mechanism and side effect are two faces of one action, which we unpack in the side-effects guide.
Why it's a once-weekly injection
Native incretins last minutes. Tirzepatide is engineered with a fatty-acid chain that binds albumin in the blood, dramatically extending its half-life to roughly five days — long enough for stable once-weekly dosing. That pharmacokinetic design is why a missed dose has a grace window and why the drug reaches steady state over several weeks rather than instantly. It also underpins the slow titration schedule that governs both efficacy and tolerability, and — on dose-tiered plans — your monthly bill. For the money side of that dose ladder, see our flat-rate vs dose-tiered guide.
Frequently asked questions
How does tirzepatide work?
Tirzepatide is a dual agonist that activates both the GLP-1 and GIP receptors — two incretin hormone pathways. This slows gastric emptying, reduces appetite, and improves glucose and fat handling, producing weight loss and cardiometabolic improvements. Semaglutide, by contrast, activates only the GLP-1 receptor.
Why is tirzepatide more effective than semaglutide?
The leading explanation is its dual mechanism: activating both GLP-1 and GIP receptors appears to produce additive metabolic effects versus GLP-1 alone. In the SURMOUNT-5 head-to-head, tirzepatide reached 20.2% mean weight loss versus 13.7% for semaglutide.
What is the difference between GLP-1 and GIP?
Both are incretin hormones released after eating that boost insulin secretion. GLP-1 also slows gastric emptying and signals fullness; GIP additionally influences fat metabolism and appetite through its own receptors. Tirzepatide engages both; semaglutide engages only GLP-1.
Why is tirzepatide injected only once a week?
It's engineered with a fatty-acid chain that binds albumin in the blood, extending its half-life to roughly five days. That allows stable once-weekly dosing, gives a grace window for missed doses, and means the drug reaches steady state over several weeks.
References
- Coskun T, et al. Tirzepatide, a dual GIP/GLP-1 receptor agonist: pharmacology and mechanism.
- Aronne LJ, et al. SURMOUNT-5 head-to-head trial. N Engl J Med. 2025.
- Eli Lilly. Zepbound (tirzepatide) Prescribing Information — clinical pharmacology.
- TirzepatidePriceGuide.com science journal, July 2026.
Clinical figures cited from published trial reports and FDA labeling; pricing figures from provider-advertised rates checked July 2026 and subject to change. This article is educational and is not medical or financial advice.